Details of the Drug

General Information of Drug (ID: DMQMBZ1)

Drug Name
Rivaroxaban
Synonyms XARELTO (TN)
Indication
Disease Entry ICD 11 Status REF
Deep vein thrombosis BD71 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 435.9
Topological Polar Surface Area (xlogp) 2.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.4 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.7 L/kg [3]
Chemical Identifiers
Formula
C19H18ClN3O5S
IUPAC Name
5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
Canonical SMILES
C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
InChIKey
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Cross-matching ID
PubChem CID
9875401
ChEBI ID
CHEBI:68579
CAS Number
366789-02-8
DrugBank ID
DB06228
TTD ID
D0KG3R
VARIDT ID
DR00227
INTEDE ID
DR1431
ACDINA ID
D00601

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Modulator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Deep vein thrombosis
ICD Disease Classification BD71
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor Xa (F10) DTT F10 4.84E-02 -0.28 -0.9
P-glycoprotein 1 (ABCB1) DTP P-GP 2.04E-02 -1.13E+00 -1.00E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 2.10E-01 3.71E-01 7.59E-01
Cytochrome P450 2J2 (CYP2J2) DME CYP2J2 1.81E-19 1.37E+00 4.29E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.51E-02 1.53E+00 1.16E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.84E-01 -1.61E-01 -3.61E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rivaroxaban
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Rivaroxaban and Danaparoid. Deep vein thrombosis [BD71] [60]
Coadministration of a Drug Treating the Disease Different from Rivaroxaban (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Rivaroxaban caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [61]
Midostaurin DMI6E0R Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [62]
Arn-509 DMT81LZ Major Increased metabolism of Rivaroxaban caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [63]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [64]
Emapalumab DMZG5WL Moderate Altered metabolism of Rivaroxaban due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [62]
Siltuximab DMGEATB Moderate Altered metabolism of Rivaroxaban due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [62]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Rivaroxaban caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [64]
Ag-221 DMS0ZBI Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [64]
Erdafitinib DMI782S Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [65]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Rivaroxaban caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [61]
Tucatinib DMBESUA Moderate Decreased metabolism of Rivaroxaban caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
PF-04449913 DMSB068 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [62]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Levomilnacipran. Chronic pain [MG30] [66]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Rivaroxaban and Regorafenib. Colorectal cancer [2B91] [62]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Intedanib. Colorectal cancer [2B91] [67]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Rivaroxaban and Ardeparin. Coronary thrombosis [BA43] [60]
Lumacaftor DMCLWDJ Major Increased metabolism of Rivaroxaban caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [63]
Ivacaftor DMZC1HS Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [61]
MK-8228 DMOB58Q Moderate Decreased metabolism of Rivaroxaban caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [64]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Rivaroxaban and Vilazodone. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Rivaroxaban and Vortioxetine. Depression [6A70-6A7Z] [66]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Rivaroxaban and Desvenlafaxine. Depression [6A70-6A7Z] [66]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Rivaroxaban and Apigenin. Discovery agent [N.A.] [68]
Stiripentol DMMSDOY Moderate Decreased metabolism of Rivaroxaban caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [64]
Tazemetostat DMWP1BH Major Increased risk of bleeding by the combination of Rivaroxaban and Tazemetostat. Follicular lymphoma [2A80] [61]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Rivaroxaban and Avapritinib. Gastrointestinal stromal tumour [2B5B] [62]
Boceprevir DMBSHMF Major Decreased metabolism of Rivaroxaban caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [64]
GS-5885 DMSL3DX Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [69]
Fostemsavir DM50ILT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [70]
Cobicistat DM6L4H2 Major Decreased clearance of Rivaroxaban due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [64]
Etravirine DMGV8QU Moderate Increased metabolism of Rivaroxaban caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [61]
BMS-201038 DMQTAGO Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [61]
Suvorexant DM0E6S3 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [61]
Crizotinib DM4F29C Moderate Decreased metabolism of Rivaroxaban caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
Brigatinib DM7W94S Moderate Increased metabolism of Rivaroxaban caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [61]
Ceritinib DMB920Z Moderate Decreased metabolism of Rivaroxaban caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [64]
PF-06463922 DMKM7EW Moderate Accelerated clearance of Rivaroxaban due to the transporter induction by PF-06463922. Lung cancer [2C25] [61]
Capmatinib DMYCXKL Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [71]
Selpercatinib DMZR15V Moderate Decreased metabolism of Rivaroxaban caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [61]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Rivaroxaban and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [72]
Idelalisib DM602WT Moderate Decreased metabolism of Rivaroxaban caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [64]
IPI-145 DMWA24P Moderate Decreased metabolism of Rivaroxaban caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [64]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Rivaroxaban and Acalabrutinib. Mature B-cell lymphoma [2A85] [73]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Rivaroxaban and Ibrutinib. Mature B-cell lymphoma [2A85] [74]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Rivaroxaban and Ponatinib. Mature B-cell lymphoma [2A85] [75]
Vemurafenib DM62UG5 Moderate Increased metabolism of Rivaroxaban caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [61]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rivaroxaban caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [61]
Lasmiditan DMXLVDT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Lasmiditan. Migraine [8A80] [76]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Rivaroxaban and Panobinostat. Multiple myeloma [2A83] [64]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Rivaroxaban and Fedratinib. Myeloproliferative neoplasm [2A20] [61]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Rivaroxaban and Ruxolitinib. Myeloproliferative neoplasm [2A20] [61]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Rivaroxaban and Vorapaxar. Myocardial infarction [BA41-BA43] [77]
Rolapitant DM8XP26 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [78]
Netupitant DMEKAYI Moderate Decreased metabolism of Rivaroxaban caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [64]
Entrectinib DMMPTLH Moderate Decreased metabolism of Rivaroxaban caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [79]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Nepafenac. Osteoarthritis [FA00-FA05] [80]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Rivaroxaban caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [81]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Rivaroxaban and MK-4827. Ovarian cancer [2C73] [62]
Abametapir DM2RX0I Moderate Decreased metabolism of Rivaroxaban caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [82]
Lefamulin DME6G97 Moderate Decreased metabolism of Rivaroxaban caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [83]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Choline salicylate. Postoperative inflammation [1A00-CA43] [84]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Rivaroxaban caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [64]
Enzalutamide DMGL19D Major Increased metabolism of Rivaroxaban caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [63]
Darolutamide DMV7YFT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [85]
Ixekizumab DMXW92T Moderate Altered metabolism of Rivaroxaban due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [62]
Tocilizumab DM7J6OR Moderate Altered metabolism of Rivaroxaban due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Rilonacept DMGLUQS Moderate Altered metabolism of Rivaroxaban due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Golimumab DMHZV7X Moderate Altered metabolism of Rivaroxaban due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Sarilumab DMOGNXY Moderate Altered metabolism of Rivaroxaban due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [62]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Rivaroxaban caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [64]
Tedizolid DMG2SKR Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [62]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Rivaroxaban caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [62]
Larotrectinib DM26CQR Moderate Decreased metabolism of Rivaroxaban caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Armodafinil DMGB035 Minor Increased metabolism of Rivaroxaban caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [86]
LEE011 DMMX75K Moderate Decreased metabolism of Rivaroxaban caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [64]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Rivaroxaban and Curcumin. Solid tumour/cancer [2A00-2F9Z] [87]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Rivaroxaban and Plicamycin. Testicular cancer [2C80] [61]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Rivaroxaban caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [88]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Rivaroxaban and Apixaban. Thrombosis [DB61-GB90] [61]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Rivaroxaban and Cangrelor. Thrombosis [DB61-GB90] [62]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Rivaroxaban and Brilinta. Thrombosis [DB61-GB90] [61]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Rivaroxaban and Cabozantinib. Thyroid cancer [2D10] [89]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Rivaroxaban and Betrixaban. Venous thromboembolism [BD72] [61]
⏷ Show the Full List of 83 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rivaroxaban 10 mg tablet 10 mg Oral Tablet Oral
Rivaroxaban 15 mg tablet 15 mg Oral Tablet Oral
Rivaroxaban 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388).
2 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
6 Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
7 Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
8 Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
19 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
20 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
21 Drug Interactions Flockhart Table
22 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
23 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
24 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
25 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
26 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
27 Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
28 Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
29 Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
30 Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
31 Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
32 Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
33 Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
34 Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
35 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
36 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
37 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
38 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
39 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
40 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
41 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
42 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
43 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
44 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
45 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
46 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
47 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
48 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
49 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
50 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
51 Pfizer. Product Development Pipeline. March 31 2009.
52 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
53 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
54 Company report (Portola)
55 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
56 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
57 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
58 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
59 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
60 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
61 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
62 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
63 Canadian Pharmacists Association.
64 Cerner Multum, Inc. "Australian Product Information.".
65 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
66 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
67 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
68 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
69 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
70 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
71 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
72 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
73 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
74 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
75 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
76 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
77 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
78 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
79 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
80 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
81 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
82 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
84 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
85 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
86 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
87 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
88 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
89 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.